News Kringle Pharma, Inc.

Equities

4884

JP3270790003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
574 ^JPY	-0.17%		+5.32%	-23.67%

Feb. 09	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI
2023	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	Feb. 08	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	Nov. 28	CI
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	Nov. 17	CI
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries	23-10-31	MT
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	23-10-30	CI
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	23-10-02	CI
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	23-09-03	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-08-30	CI
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	23-08-13	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-05-29	CI
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment	23-04-14	MT
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	23-04-13	CI
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment	23-03-14	MT
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	23-03-12	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-02-27	CI
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine	23-01-18	MT
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment	23-01-18	MT
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	23-01-16	CI
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	23-01-12	CI
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023	22-12-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kringle Pharma, Inc.

Equities

4884

JP3270790003

Summary

Filters